Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells

Research output: Contribution to journalArticlepeer-review


Chimeric antigen receptor- (CAR-) based immunotherapy has been under development for almost 25 years, over which period it has progressed from a new but cumbersome technology to an emerging therapeutic modality for malignant disease. The approach involves the genetic engineering of fusion receptors (CARs) that couple the HLA-independent binding of cell surface target molecules to the delivery of a tailored activating signal to host immune cells. Engineered CARs are delivered most commonly to peripheral blood T cells using a range of vector systems, most commonly integrating viral vectors. Preclinical refinement of this approach has proceeded over several years to the point that clinical testing is now being undertaken at several centres, using increasingly sophisticated and therapeutically successful genetic payloads. This paper considers several aspects of the pre-clinical and clinical development of CAR-based immunotherapy and how this technology is acquiring an increasing niche in the treatment of both solid and haematological malignancies.
Original languageEnglish
Article number278093
Number of pages23
JournalISRN oncology
Publication statusPublished - 2012


Dive into the research topics of 'Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells'. Together they form a unique fingerprint.

Cite this